Genesis MedTech's iReach Omnia Receives NMPA Approval for Rectal Cancer Surgery

Genesis MedTech’s iReach Omnia Receives NMPA Approval for Rectal Cancer Surgery

Singapore-based medical device company Genesis MedTech has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its groundbreaking device, the iReach Omnia. This marks a significant milestone as iReach Omnia is the world’s first powered stapler with 90° articulation capability.

Enhancing Surgical Precision in Low Rectal Cancer Treatment
Surgical resection remains the primary treatment method for low rectal cancer. However, surgeons often encounter significant challenges in completely removing tumors, achieving clear margins in confined spaces, preserving sphincter function, and minimizing complications such as anastomotic leakage. The iReach Omnia’s unique 90° articulation capability is designed to address these challenges head-on.

Advantages of iReach Omnia in Rectal Cancer Surgery
The iReach Omnia’s ability to perform precise vertical cutting and stapling in low rectal resections is a game-changer. It reduces the risk of leakage and other postoperative complications, ultimately enhancing long-term patient outcomes. This approval in China opens up new possibilities for improved surgical treatments and better patient care in the country.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry